Cota specializes in leveraging real-world data (RWD) to enhance cancer care and research. Their comprehensive database includes over 2 million patient records across various cancer types, treatment settings, and demographics, which is regularly updated to maintain quality and relevance. This extensive dataset supports oncology research and development teams by enabling them to generate and test hypotheses, identify treatment response predictors, and expedite drug development timelines. Additionally, Cota's data is utilized by regulatory teams to augment clinical trials, providing external validity and supporting regulatory submissions with real-world benchmarks.

Furthermore, Cota offers valuable insights for commercial teams and health economics and outcomes research (HEOR) teams. Their data assists in validating commercial strategies, conducting post-marketing studies, and responding to inquiries from health authorities and payers. Cota's oncology analytics solutions also help cancer centers and oncologists make sense of fragmented electronic health record (EHR) data, ultimately aiming to improve patient outcomes and treatment protocols. By focusing on real-world insights, Cota is positioned as a key player in transforming cancer care through data-driven approaches.

United States

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data.

By using our proprietary technology, advanced analytics and deep expertise to organize complex data, we provide a comprehensive picture of cancer that can be used to advance care and research.  

‍We believe that everyone touched by cancer deserves a clear path to care. Together, we can make that vision a reality.  

Cota

Company Details